nodes	percent_of_prediction	percent_of_DWPC	metapath
Azelastine—Buclizine—Imatinib—hematologic cancer	0.16	0.524	CrCrCtD
Azelastine—Meclizine—Imatinib—hematologic cancer	0.146	0.476	CrCrCtD
Azelastine—ABCB1—hematologic cancer	0.0445	1	CbGaD
Azelastine—CYP2A6—Methoxsalen—hematologic cancer	0.013	0.0291	CbGbCtD
Azelastine—CYP1A2—Anagrelide—hematologic cancer	0.0111	0.0248	CbGbCtD
Azelastine—CYP1A1—Methoxsalen—hematologic cancer	0.0111	0.0248	CbGbCtD
Azelastine—CYP2B6—Thiotepa—hematologic cancer	0.0109	0.0243	CbGbCtD
Azelastine—CYP1A1—Bortezomib—hematologic cancer	0.0105	0.0236	CbGbCtD
Azelastine—CYP1A1—Daunorubicin—hematologic cancer	0.0101	0.0226	CbGbCtD
Azelastine—CYP2A6—Ifosfamide—hematologic cancer	0.00946	0.0212	CbGbCtD
Azelastine—CYP1A1—Thalidomide—hematologic cancer	0.00918	0.0206	CbGbCtD
Azelastine—CYP1A1—Dacarbazine—hematologic cancer	0.0079	0.0177	CbGbCtD
Azelastine—CYP2E1—Thalidomide—hematologic cancer	0.00709	0.0159	CbGbCtD
Azelastine—CYP2C9—Bexarotene—hematologic cancer	0.00692	0.0155	CbGbCtD
Azelastine—ABCB1—Lenalidomide—hematologic cancer	0.00672	0.0151	CbGbCtD
Azelastine—CYP2A6—Prednisolone—hematologic cancer	0.00631	0.0141	CbGbCtD
Azelastine—CYP1A1—Dasatinib—hematologic cancer	0.0062	0.0139	CbGbCtD
Azelastine—CYP2B6—Ifosfamide—hematologic cancer	0.00616	0.0138	CbGbCtD
Azelastine—CYP2E1—Dacarbazine—hematologic cancer	0.0061	0.0137	CbGbCtD
Azelastine—CYP2C8—Bortezomib—hematologic cancer	0.00608	0.0136	CbGbCtD
Azelastine—CYP3A5—Daunorubicin—hematologic cancer	0.00605	0.0136	CbGbCtD
Azelastine—CYP2D6—Lomustine—hematologic cancer	0.00588	0.0132	CbGbCtD
Azelastine—CYP1A2—Carmustine—hematologic cancer	0.00582	0.0131	CbGbCtD
Azelastine—CYP2C9—Idarubicin—hematologic cancer	0.00574	0.0129	CbGbCtD
Azelastine—CYP3A5—Thalidomide—hematologic cancer	0.00551	0.0124	CbGbCtD
Azelastine—CYP2B6—Nilotinib—hematologic cancer	0.00535	0.012	CbGbCtD
Azelastine—CYP3A5—Teniposide—hematologic cancer	0.00526	0.0118	CbGbCtD
Azelastine—CYP2D6—Idarubicin—hematologic cancer	0.00524	0.0118	CbGbCtD
Azelastine—CYP2C19—Bortezomib—hematologic cancer	0.0051	0.0114	CbGbCtD
Azelastine—CYP1A2—Methoxsalen—hematologic cancer	0.00495	0.0111	CbGbCtD
Azelastine—CYP3A5—Ifosfamide—hematologic cancer	0.00485	0.0109	CbGbCtD
Azelastine—CYP2E1—Mitoxantrone—hematologic cancer	0.00473	0.0106	CbGbCtD
Azelastine—CYP1A2—Bortezomib—hematologic cancer	0.00471	0.0106	CbGbCtD
Azelastine—CYP2C8—Ifosfamide—hematologic cancer	0.00466	0.0105	CbGbCtD
Azelastine—CYP3A5—Imatinib—hematologic cancer	0.00463	0.0104	CbGbCtD
Azelastine—CYP1A2—Daunorubicin—hematologic cancer	0.0045	0.0101	CbGbCtD
Azelastine—CYP2D6—Hydroxyurea—hematologic cancer	0.00446	0.01	CbGbCtD
Azelastine—CYP2C19—Thalidomide—hematologic cancer	0.00445	0.00997	CbGbCtD
Azelastine—CYP1A2—Alitretinoin—hematologic cancer	0.00441	0.00989	CbGbCtD
Azelastine—CYP2C9—Bortezomib—hematologic cancer	0.00424	0.00951	CbGbCtD
Azelastine—CYP2C19—Teniposide—hematologic cancer	0.00424	0.00951	CbGbCtD
Azelastine—CYP1A2—Thalidomide—hematologic cancer	0.0041	0.0092	CbGbCtD
Azelastine—CYP2C8—Nilotinib—hematologic cancer	0.00405	0.00908	CbGbCtD
Azelastine—CYP3A4—Bexarotene—hematologic cancer	0.00402	0.00902	CbGbCtD
Azelastine—ABCB1—Daunorubicin—hematologic cancer	0.00394	0.00883	CbGbCtD
Azelastine—CYP2C19—Ifosfamide—hematologic cancer	0.00391	0.00877	CbGbCtD
Azelastine—CYP2D6—Bortezomib—hematologic cancer	0.00388	0.0087	CbGbCtD
Azelastine—ABCB1—Alitretinoin—hematologic cancer	0.00386	0.00865	CbGbCtD
Azelastine—CYP3A4—Busulfan—hematologic cancer	0.00374	0.00839	CbGbCtD
Azelastine—CYP3A4—Lomustine—hematologic cancer	0.00374	0.00839	CbGbCtD
Azelastine—CYP2C19—Imatinib—hematologic cancer	0.00374	0.00838	CbGbCtD
Azelastine—CYP3A5—Dasatinib—hematologic cancer	0.00372	0.00835	CbGbCtD
Azelastine—CYP2A6—Dexamethasone—hematologic cancer	0.00372	0.00834	CbGbCtD
Azelastine—CYP2C9—Thalidomide—hematologic cancer	0.0037	0.00829	CbGbCtD
Azelastine—CYP2B6—Irinotecan—hematologic cancer	0.00367	0.00824	CbGbCtD
Azelastine—CYP1A2—Dacarbazine—hematologic cancer	0.00353	0.00791	CbGbCtD
Azelastine—CYP2C9—Teniposide—hematologic cancer	0.00353	0.0079	CbGbCtD
Azelastine—CYP1A2—Imatinib—hematologic cancer	0.00345	0.00773	CbGbCtD
Azelastine—CYP3A4—Thiotepa—hematologic cancer	0.00333	0.00748	CbGbCtD
Azelastine—CYP2C9—Ifosfamide—hematologic cancer	0.00325	0.0073	CbGbCtD
Azelastine—CYP1A1—Dexamethasone—hematologic cancer	0.00318	0.00712	CbGbCtD
Azelastine—CYP2C9—Imatinib—hematologic cancer	0.00311	0.00697	CbGbCtD
Azelastine—ABCB1—Imatinib—hematologic cancer	0.00302	0.00676	CbGbCtD
Azelastine—CYP2B6—Cisplatin—hematologic cancer	0.003	0.00672	CbGbCtD
Azelastine—CYP2E1—Etoposide—hematologic cancer	0.00298	0.00669	CbGbCtD
Azelastine—CYP3A5—Irinotecan—hematologic cancer	0.00289	0.00649	CbGbCtD
Azelastine—CYP2D6—Imatinib—hematologic cancer	0.00284	0.00637	CbGbCtD
Azelastine—CYP2C9—Nilotinib—hematologic cancer	0.00282	0.00633	CbGbCtD
Azelastine—CYP1A2—Dasatinib—hematologic cancer	0.00277	0.00621	CbGbCtD
Azelastine—ABCB1—Nilotinib—hematologic cancer	0.00274	0.00615	CbGbCtD
Azelastine—ABCB1—Vinorelbine—hematologic cancer	0.00272	0.00609	CbGbCtD
Azelastine—CYP3A4—Methoxsalen—hematologic cancer	0.00259	0.00581	CbGbCtD
Azelastine—CYP2D6—Nilotinib—hematologic cancer	0.00258	0.00579	CbGbCtD
Azelastine—CYP2D6—Vinorelbine—hematologic cancer	0.00256	0.00574	CbGbCtD
Azelastine—CYP3A5—Vincristine—hematologic cancer	0.00253	0.00567	CbGbCtD
Azelastine—CYP3A4—Bortezomib—hematologic cancer	0.00247	0.00553	CbGbCtD
Azelastine—CYP2C19—Prednisone—hematologic cancer	0.00246	0.00552	CbGbCtD
Azelastine—CYP2E1—Dexamethasone—hematologic cancer	0.00245	0.0055	CbGbCtD
Azelastine—ABCB1—Dasatinib—hematologic cancer	0.00242	0.00543	CbGbCtD
Azelastine—CYP2B6—Dexamethasone—hematologic cancer	0.00242	0.00543	CbGbCtD
Azelastine—ABCB1—Mitoxantrone—hematologic cancer	0.00239	0.00537	CbGbCtD
Azelastine—CYP3A4—Daunorubicin—hematologic cancer	0.00236	0.00529	CbGbCtD
Azelastine—CYP3A5—Etoposide—hematologic cancer	0.00232	0.0052	CbGbCtD
Azelastine—CYP2C8—Etoposide—hematologic cancer	0.00223	0.005	CbGbCtD
Azelastine—ABCB1—Betamethasone—hematologic cancer	0.00213	0.00478	CbGbCtD
Azelastine—ABCB1—Gemcitabine—hematologic cancer	0.00211	0.00474	CbGbCtD
Azelastine—ABCB1—Prednisolone—hematologic cancer	0.0021	0.00472	CbGbCtD
Azelastine—CYP3A4—Cytarabine—hematologic cancer	0.00208	0.00467	CbGbCtD
Azelastine—CYP3A4—Teniposide—hematologic cancer	0.00205	0.0046	CbGbCtD
Azelastine—CYP2B6—Doxorubicin—hematologic cancer	0.00201	0.0045	CbGbCtD
Azelastine—ABCB1—Prednisone—hematologic cancer	0.00199	0.00446	CbGbCtD
Azelastine—CYP3A5—Dexamethasone—hematologic cancer	0.00191	0.00427	CbGbCtD
Azelastine—CYP3A4—Ifosfamide—hematologic cancer	0.00189	0.00424	CbGbCtD
Azelastine—ABCB1—Irinotecan—hematologic cancer	0.00188	0.00422	CbGbCtD
Azelastine—CYP2C8—Dexamethasone—hematologic cancer	0.00183	0.00411	CbGbCtD
Azelastine—CYP3A4—Imatinib—hematologic cancer	0.00181	0.00405	CbGbCtD
Azelastine—CYP1A2—Etoposide—hematologic cancer	0.00173	0.00387	CbGbCtD
Azelastine—CYP3A4—Ruxolitinib—hematologic cancer	0.0017	0.00382	CbGbCtD
Azelastine—ABCB1—Vinblastine—hematologic cancer	0.00168	0.00376	CbGbCtD
Azelastine—ABCB1—Vincristine—hematologic cancer	0.00165	0.00369	CbGbCtD
Azelastine—CYP3A4—Nilotinib—hematologic cancer	0.00164	0.00368	CbGbCtD
Azelastine—CYP3A4—Vinorelbine—hematologic cancer	0.00163	0.00365	CbGbCtD
Azelastine—CYP2C9—Cisplatin—hematologic cancer	0.00158	0.00355	CbGbCtD
Azelastine—CYP2D6—Vinblastine—hematologic cancer	0.00158	0.00354	CbGbCtD
Azelastine—CYP2C19—Dexamethasone—hematologic cancer	0.00154	0.00345	CbGbCtD
Azelastine—ABCB1—Cisplatin—hematologic cancer	0.00154	0.00344	CbGbCtD
Azelastine—HRH3—hematopoietic system—hematologic cancer	0.00151	0.106	CbGeAlD
Azelastine—ABCB1—Etoposide—hematologic cancer	0.00151	0.00338	CbGbCtD
Azelastine—CYP3A4—Triamcinolone—hematologic cancer	0.00149	0.00334	CbGbCtD
Azelastine—CYP3A4—Dasatinib—hematologic cancer	0.00145	0.00325	CbGbCtD
Azelastine—CYP3A4—Mitoxantrone—hematologic cancer	0.00143	0.00321	CbGbCtD
Azelastine—CYP2C9—Dexamethasone—hematologic cancer	0.00128	0.00287	CbGbCtD
Azelastine—CYP3A4—Betamethasone—hematologic cancer	0.00128	0.00287	CbGbCtD
Azelastine—CYP3A4—Prednisolone—hematologic cancer	0.00126	0.00283	CbGbCtD
Azelastine—ABCB1—Dexamethasone—hematologic cancer	0.00124	0.00278	CbGbCtD
Azelastine—CYP3A4—Prednisone—hematologic cancer	0.00119	0.00267	CbGbCtD
Azelastine—CYP2D6—Dexamethasone—hematologic cancer	0.00117	0.00262	CbGbCtD
Azelastine—CYP3A4—Irinotecan—hematologic cancer	0.00113	0.00253	CbGbCtD
Azelastine—ABCB1—Doxorubicin—hematologic cancer	0.00103	0.00231	CbGbCtD
Azelastine—CYP3A4—Vinblastine—hematologic cancer	0.001	0.00225	CbGbCtD
Azelastine—HRH3—blood—hematologic cancer	0.001	0.0705	CbGeAlD
Azelastine—ABCB1—Methotrexate—hematologic cancer	0.000997	0.00224	CbGbCtD
Azelastine—CYP3A4—Vincristine—hematologic cancer	0.000987	0.00221	CbGbCtD
Azelastine—CYP2D6—Doxorubicin—hematologic cancer	0.00097	0.00217	CbGbCtD
Azelastine—CYP3A4—Etoposide—hematologic cancer	0.000904	0.00203	CbGbCtD
Azelastine—CYP3A4—Dexamethasone—hematologic cancer	0.000743	0.00167	CbGbCtD
Azelastine—CYP3A4—Doxorubicin—hematologic cancer	0.000617	0.00138	CbGbCtD
Azelastine—CYP2C19—hematopoietic system—hematologic cancer	0.000459	0.0322	CbGeAlD
Azelastine—KCNH2—hematopoietic system—hematologic cancer	0.000438	0.0307	CbGeAlD
Azelastine—CYP2A6—lung—hematologic cancer	0.000414	0.0291	CbGeAlD
Azelastine—CYP2C8—hematopoietic system—hematologic cancer	0.0004	0.0281	CbGeAlD
Azelastine—CYP1A2—hematopoietic system—hematologic cancer	0.000375	0.0263	CbGeAlD
Azelastine—CYP1A1—hematopoietic system—hematologic cancer	0.00037	0.0259	CbGeAlD
Azelastine—CYP3A5—hematopoietic system—hematologic cancer	0.000361	0.0254	CbGeAlD
Azelastine—CYP2B6—hematopoietic system—hematologic cancer	0.000359	0.0252	CbGeAlD
Azelastine—CYP2C9—hematopoietic system—hematologic cancer	0.000356	0.025	CbGeAlD
Azelastine—HRH1—hematopoietic system—hematologic cancer	0.000351	0.0246	CbGeAlD
Azelastine—CYP2E1—hematopoietic system—hematologic cancer	0.000337	0.0237	CbGeAlD
Azelastine—CYP2C19—blood—hematologic cancer	0.000304	0.0213	CbGeAlD
Azelastine—KCNH2—blood—hematologic cancer	0.00029	0.0204	CbGeAlD
Azelastine—KCNH2—bone marrow—hematologic cancer	0.00028	0.0197	CbGeAlD
Azelastine—CYP2B6—gonad—hematologic cancer	0.000273	0.0192	CbGeAlD
Azelastine—CYP3A4—hematopoietic system—hematologic cancer	0.000271	0.019	CbGeAlD
Azelastine—CYP2D6—hematopoietic system—hematologic cancer	0.000267	0.0187	CbGeAlD
Azelastine—CYP2C8—blood—hematologic cancer	0.000265	0.0186	CbGeAlD
Azelastine—CYP1A2—blood—hematologic cancer	0.000248	0.0174	CbGeAlD
Azelastine—CYP1A1—blood—hematologic cancer	0.000245	0.0172	CbGeAlD
Azelastine—KCNH2—testis—hematologic cancer	0.00024	0.0168	CbGeAlD
Azelastine—CYP3A5—blood—hematologic cancer	0.000239	0.0168	CbGeAlD
Azelastine—CYP2B6—blood—hematologic cancer	0.000238	0.0167	CbGeAlD
Azelastine—CYP2C9—blood—hematologic cancer	0.000236	0.0165	CbGeAlD
Azelastine—CYP2E1—blood—hematologic cancer	0.000223	0.0157	CbGeAlD
Azelastine—CYP2C8—testis—hematologic cancer	0.000219	0.0154	CbGeAlD
Azelastine—CYP1A2—lung—hematologic cancer	0.000218	0.0153	CbGeAlD
Azelastine—CYP1A1—lung—hematologic cancer	0.000215	0.0151	CbGeAlD
Azelastine—CYP3A5—lung—hematologic cancer	0.00021	0.0147	CbGeAlD
Azelastine—CYP2B6—lung—hematologic cancer	0.000209	0.0146	CbGeAlD
Azelastine—HRH1—lung—hematologic cancer	0.000204	0.0143	CbGeAlD
Azelastine—CYP2B6—testis—hematologic cancer	0.000197	0.0138	CbGeAlD
Azelastine—CYP2E1—lung—hematologic cancer	0.000196	0.0137	CbGeAlD
Azelastine—HRH1—testis—hematologic cancer	0.000192	0.0135	CbGeAlD
Azelastine—ABCB1—hematopoietic system—hematologic cancer	0.000192	0.0135	CbGeAlD
Azelastine—CYP2E1—testis—hematologic cancer	0.000185	0.013	CbGeAlD
Azelastine—CYP3A4—blood—hematologic cancer	0.00018	0.0126	CbGeAlD
Azelastine—CYP2D6—blood—hematologic cancer	0.000177	0.0124	CbGeAlD
Azelastine—KCNH2—lymph node—hematologic cancer	0.000174	0.0122	CbGeAlD
Azelastine—CYP1A1—lymph node—hematologic cancer	0.000147	0.0103	CbGeAlD
Azelastine—CYP2D6—testis—hematologic cancer	0.000146	0.0103	CbGeAlD
Azelastine—ABCB1—gonad—hematologic cancer	0.000146	0.0102	CbGeAlD
Azelastine—HRH1—lymph node—hematologic cancer	0.000139	0.00978	CbGeAlD
Azelastine—ABCB1—blood—hematologic cancer	0.000127	0.00893	CbGeAlD
Azelastine—ABCB1—bone marrow—hematologic cancer	0.000123	0.00864	CbGeAlD
Azelastine—ABCB1—lung—hematologic cancer	0.000111	0.00783	CbGeAlD
Azelastine—ABCB1—testis—hematologic cancer	0.000105	0.00739	CbGeAlD
Azelastine—ABCB1—lymph node—hematologic cancer	7.62e-05	0.00535	CbGeAlD
Azelastine—Vertigo—Prednisone—hematologic cancer	2.53e-05	0.000183	CcSEcCtD
Azelastine—Eye disorder—Methotrexate—hematologic cancer	2.52e-05	0.000183	CcSEcCtD
Azelastine—Hypoaesthesia—Epirubicin—hematologic cancer	2.51e-05	0.000182	CcSEcCtD
Azelastine—Vomiting—Vincristine—hematologic cancer	2.51e-05	0.000182	CcSEcCtD
Azelastine—Asthenia—Cisplatin—hematologic cancer	2.51e-05	0.000182	CcSEcCtD
Azelastine—Pharyngitis—Epirubicin—hematologic cancer	2.51e-05	0.000182	CcSEcCtD
Azelastine—Fatigue—Triamcinolone—hematologic cancer	2.5e-05	0.000181	CcSEcCtD
Azelastine—Rash—Vincristine—hematologic cancer	2.49e-05	0.000181	CcSEcCtD
Azelastine—Dermatitis—Vincristine—hematologic cancer	2.49e-05	0.00018	CcSEcCtD
Azelastine—Pain—Triamcinolone—hematologic cancer	2.48e-05	0.00018	CcSEcCtD
Azelastine—Haematuria—Doxorubicin—hematologic cancer	2.48e-05	0.00018	CcSEcCtD
Azelastine—Headache—Vincristine—hematologic cancer	2.48e-05	0.000179	CcSEcCtD
Azelastine—Nausea—Carmustine—hematologic cancer	2.46e-05	0.000178	CcSEcCtD
Azelastine—Epistaxis—Doxorubicin—hematologic cancer	2.45e-05	0.000178	CcSEcCtD
Azelastine—Vomiting—Irinotecan—hematologic cancer	2.45e-05	0.000177	CcSEcCtD
Azelastine—Vomiting—Mitoxantrone—hematologic cancer	2.45e-05	0.000177	CcSEcCtD
Azelastine—Sinusitis—Doxorubicin—hematologic cancer	2.44e-05	0.000177	CcSEcCtD
Azelastine—Nausea—Alitretinoin—hematologic cancer	2.44e-05	0.000177	CcSEcCtD
Azelastine—Visual impairment—Epirubicin—hematologic cancer	2.43e-05	0.000176	CcSEcCtD
Azelastine—Hypertension—Prednisone—hematologic cancer	2.43e-05	0.000176	CcSEcCtD
Azelastine—Rash—Irinotecan—hematologic cancer	2.43e-05	0.000176	CcSEcCtD
Azelastine—Rash—Mitoxantrone—hematologic cancer	2.43e-05	0.000176	CcSEcCtD
Azelastine—Dermatitis—Mitoxantrone—hematologic cancer	2.42e-05	0.000176	CcSEcCtD
Azelastine—Dermatitis—Irinotecan—hematologic cancer	2.42e-05	0.000176	CcSEcCtD
Azelastine—Headache—Mitoxantrone—hematologic cancer	2.41e-05	0.000175	CcSEcCtD
Azelastine—Headache—Irinotecan—hematologic cancer	2.41e-05	0.000175	CcSEcCtD
Azelastine—Nausea—Ifosfamide—hematologic cancer	2.41e-05	0.000174	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	2.4e-05	0.000174	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	2.4e-05	0.000174	CcSEcCtD
Azelastine—Myalgia—Prednisone—hematologic cancer	2.39e-05	0.000173	CcSEcCtD
Azelastine—Feeling abnormal—Triamcinolone—hematologic cancer	2.39e-05	0.000173	CcSEcCtD
Azelastine—Diarrhoea—Cisplatin—hematologic cancer	2.39e-05	0.000173	CcSEcCtD
Azelastine—Anxiety—Prednisone—hematologic cancer	2.38e-05	0.000173	CcSEcCtD
Azelastine—Vomiting—Gemcitabine—hematologic cancer	2.38e-05	0.000173	CcSEcCtD
Azelastine—Paraesthesia—Betamethasone—hematologic cancer	2.37e-05	0.000171	CcSEcCtD
Azelastine—Paraesthesia—Dexamethasone—hematologic cancer	2.37e-05	0.000171	CcSEcCtD
Azelastine—Discomfort—Prednisone—hematologic cancer	2.36e-05	0.000171	CcSEcCtD
Azelastine—Rash—Gemcitabine—hematologic cancer	2.36e-05	0.000171	CcSEcCtD
Azelastine—Dermatitis—Gemcitabine—hematologic cancer	2.36e-05	0.000171	CcSEcCtD
Azelastine—Eye disorder—Epirubicin—hematologic cancer	2.36e-05	0.000171	CcSEcCtD
Azelastine—Hypersensitivity—Etoposide—hematologic cancer	2.36e-05	0.000171	CcSEcCtD
Azelastine—Headache—Gemcitabine—hematologic cancer	2.35e-05	0.00017	CcSEcCtD
Azelastine—Nausea—Vincristine—hematologic cancer	2.35e-05	0.00017	CcSEcCtD
Azelastine—Flushing—Epirubicin—hematologic cancer	2.34e-05	0.00017	CcSEcCtD
Azelastine—Rhinitis—Doxorubicin—hematologic cancer	2.34e-05	0.00017	CcSEcCtD
Azelastine—Hypersensitivity—Prednisolone—hematologic cancer	2.33e-05	0.000169	CcSEcCtD
Azelastine—Hypoaesthesia—Doxorubicin—hematologic cancer	2.32e-05	0.000169	CcSEcCtD
Azelastine—Pharyngitis—Doxorubicin—hematologic cancer	2.32e-05	0.000168	CcSEcCtD
Azelastine—Dysgeusia—Methotrexate—hematologic cancer	2.3e-05	0.000167	CcSEcCtD
Azelastine—Asthenia—Etoposide—hematologic cancer	2.3e-05	0.000166	CcSEcCtD
Azelastine—Body temperature increased—Triamcinolone—hematologic cancer	2.29e-05	0.000166	CcSEcCtD
Azelastine—Anaphylactic shock—Prednisone—hematologic cancer	2.29e-05	0.000166	CcSEcCtD
Azelastine—Nausea—Mitoxantrone—hematologic cancer	2.29e-05	0.000166	CcSEcCtD
Azelastine—Nausea—Irinotecan—hematologic cancer	2.29e-05	0.000166	CcSEcCtD
Azelastine—Infection—Prednisone—hematologic cancer	2.28e-05	0.000165	CcSEcCtD
Azelastine—Back pain—Methotrexate—hematologic cancer	2.27e-05	0.000165	CcSEcCtD
Azelastine—Fatigue—Dexamethasone—hematologic cancer	2.27e-05	0.000165	CcSEcCtD
Azelastine—Fatigue—Betamethasone—hematologic cancer	2.27e-05	0.000165	CcSEcCtD
Azelastine—Pruritus—Etoposide—hematologic cancer	2.26e-05	0.000164	CcSEcCtD
Azelastine—Pain—Dexamethasone—hematologic cancer	2.25e-05	0.000163	CcSEcCtD
Azelastine—Pain—Betamethasone—hematologic cancer	2.25e-05	0.000163	CcSEcCtD
Azelastine—Visual impairment—Doxorubicin—hematologic cancer	2.25e-05	0.000163	CcSEcCtD
Azelastine—Tachycardia—Prednisone—hematologic cancer	2.24e-05	0.000162	CcSEcCtD
Azelastine—Nausea—Gemcitabine—hematologic cancer	2.23e-05	0.000161	CcSEcCtD
Azelastine—Vomiting—Cisplatin—hematologic cancer	2.22e-05	0.000161	CcSEcCtD
Azelastine—Vision blurred—Methotrexate—hematologic cancer	2.21e-05	0.00016	CcSEcCtD
Azelastine—Rash—Cisplatin—hematologic cancer	2.2e-05	0.00016	CcSEcCtD
Azelastine—Dermatitis—Cisplatin—hematologic cancer	2.2e-05	0.00016	CcSEcCtD
Azelastine—Diarrhoea—Etoposide—hematologic cancer	2.19e-05	0.000159	CcSEcCtD
Azelastine—Eye disorder—Doxorubicin—hematologic cancer	2.18e-05	0.000158	CcSEcCtD
Azelastine—Ill-defined disorder—Methotrexate—hematologic cancer	2.18e-05	0.000158	CcSEcCtD
Azelastine—Feeling abnormal—Dexamethasone—hematologic cancer	2.17e-05	0.000157	CcSEcCtD
Azelastine—Feeling abnormal—Betamethasone—hematologic cancer	2.17e-05	0.000157	CcSEcCtD
Azelastine—Flushing—Doxorubicin—hematologic cancer	2.17e-05	0.000157	CcSEcCtD
Azelastine—Tension—Epirubicin—hematologic cancer	2.16e-05	0.000156	CcSEcCtD
Azelastine—Gastrointestinal pain—Betamethasone—hematologic cancer	2.15e-05	0.000156	CcSEcCtD
Azelastine—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.15e-05	0.000156	CcSEcCtD
Azelastine—Dysgeusia—Epirubicin—hematologic cancer	2.15e-05	0.000156	CcSEcCtD
Azelastine—Hypersensitivity—Triamcinolone—hematologic cancer	2.14e-05	0.000155	CcSEcCtD
Azelastine—Nervousness—Epirubicin—hematologic cancer	2.14e-05	0.000155	CcSEcCtD
Azelastine—Back pain—Epirubicin—hematologic cancer	2.13e-05	0.000154	CcSEcCtD
Azelastine—Malaise—Methotrexate—hematologic cancer	2.12e-05	0.000154	CcSEcCtD
Azelastine—Dizziness—Etoposide—hematologic cancer	2.12e-05	0.000153	CcSEcCtD
Azelastine—Vertigo—Methotrexate—hematologic cancer	2.11e-05	0.000153	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.09e-05	0.000152	CcSEcCtD
Azelastine—Dizziness—Prednisolone—hematologic cancer	2.09e-05	0.000151	CcSEcCtD
Azelastine—Asthenia—Triamcinolone—hematologic cancer	2.08e-05	0.000151	CcSEcCtD
Azelastine—Body temperature increased—Betamethasone—hematologic cancer	2.08e-05	0.000151	CcSEcCtD
Azelastine—Abdominal pain—Betamethasone—hematologic cancer	2.08e-05	0.000151	CcSEcCtD
Azelastine—Abdominal pain—Dexamethasone—hematologic cancer	2.08e-05	0.000151	CcSEcCtD
Azelastine—Body temperature increased—Dexamethasone—hematologic cancer	2.08e-05	0.000151	CcSEcCtD
Azelastine—Nausea—Cisplatin—hematologic cancer	2.08e-05	0.00015	CcSEcCtD
Azelastine—Vision blurred—Epirubicin—hematologic cancer	2.07e-05	0.00015	CcSEcCtD
Azelastine—Paraesthesia—Prednisone—hematologic cancer	2.06e-05	0.000149	CcSEcCtD
Azelastine—Pruritus—Triamcinolone—hematologic cancer	2.05e-05	0.000149	CcSEcCtD
Azelastine—Cough—Methotrexate—hematologic cancer	2.05e-05	0.000149	CcSEcCtD
Azelastine—Ill-defined disorder—Epirubicin—hematologic cancer	2.04e-05	0.000148	CcSEcCtD
Azelastine—Vomiting—Etoposide—hematologic cancer	2.03e-05	0.000148	CcSEcCtD
Azelastine—Agitation—Epirubicin—hematologic cancer	2.02e-05	0.000146	CcSEcCtD
Azelastine—Rash—Etoposide—hematologic cancer	2.02e-05	0.000146	CcSEcCtD
Azelastine—Dermatitis—Etoposide—hematologic cancer	2.02e-05	0.000146	CcSEcCtD
Azelastine—Headache—Etoposide—hematologic cancer	2.01e-05	0.000145	CcSEcCtD
Azelastine—Chest pain—Methotrexate—hematologic cancer	2e-05	0.000145	CcSEcCtD
Azelastine—Myalgia—Methotrexate—hematologic cancer	2e-05	0.000145	CcSEcCtD
Azelastine—Tension—Doxorubicin—hematologic cancer	2e-05	0.000145	CcSEcCtD
Azelastine—Dysgeusia—Doxorubicin—hematologic cancer	1.99e-05	0.000144	CcSEcCtD
Azelastine—Rash—Prednisolone—hematologic cancer	1.99e-05	0.000144	CcSEcCtD
Azelastine—Dermatitis—Prednisolone—hematologic cancer	1.99e-05	0.000144	CcSEcCtD
Azelastine—Malaise—Epirubicin—hematologic cancer	1.98e-05	0.000144	CcSEcCtD
Azelastine—Fatigue—Prednisone—hematologic cancer	1.98e-05	0.000143	CcSEcCtD
Azelastine—Headache—Prednisolone—hematologic cancer	1.98e-05	0.000143	CcSEcCtD
Azelastine—Discomfort—Methotrexate—hematologic cancer	1.98e-05	0.000143	CcSEcCtD
Azelastine—Nervousness—Doxorubicin—hematologic cancer	1.98e-05	0.000143	CcSEcCtD
Azelastine—Vertigo—Epirubicin—hematologic cancer	1.97e-05	0.000143	CcSEcCtD
Azelastine—Back pain—Doxorubicin—hematologic cancer	1.97e-05	0.000143	CcSEcCtD
Azelastine—Constipation—Prednisone—hematologic cancer	1.96e-05	0.000142	CcSEcCtD
Azelastine—Palpitations—Epirubicin—hematologic cancer	1.94e-05	0.000141	CcSEcCtD
Azelastine—Confusional state—Methotrexate—hematologic cancer	1.93e-05	0.00014	CcSEcCtD
Azelastine—Dizziness—Triamcinolone—hematologic cancer	1.92e-05	0.000139	CcSEcCtD
Azelastine—Cough—Epirubicin—hematologic cancer	1.92e-05	0.000139	CcSEcCtD
Azelastine—Anaphylactic shock—Methotrexate—hematologic cancer	1.92e-05	0.000139	CcSEcCtD
Azelastine—Vision blurred—Doxorubicin—hematologic cancer	1.92e-05	0.000139	CcSEcCtD
Azelastine—Infection—Methotrexate—hematologic cancer	1.9e-05	0.000138	CcSEcCtD
Azelastine—Nausea—Etoposide—hematologic cancer	1.9e-05	0.000138	CcSEcCtD
Azelastine—Hypertension—Epirubicin—hematologic cancer	1.9e-05	0.000138	CcSEcCtD
Azelastine—Feeling abnormal—Prednisone—hematologic cancer	1.89e-05	0.000137	CcSEcCtD
Azelastine—Asthenia—Betamethasone—hematologic cancer	1.89e-05	0.000137	CcSEcCtD
Azelastine—Asthenia—Dexamethasone—hematologic cancer	1.89e-05	0.000137	CcSEcCtD
Azelastine—Ill-defined disorder—Doxorubicin—hematologic cancer	1.89e-05	0.000137	CcSEcCtD
Azelastine—Gastrointestinal pain—Prednisone—hematologic cancer	1.88e-05	0.000136	CcSEcCtD
Azelastine—Nausea—Prednisolone—hematologic cancer	1.88e-05	0.000136	CcSEcCtD
Azelastine—Chest pain—Epirubicin—hematologic cancer	1.87e-05	0.000136	CcSEcCtD
Azelastine—Myalgia—Epirubicin—hematologic cancer	1.87e-05	0.000136	CcSEcCtD
Azelastine—Agitation—Doxorubicin—hematologic cancer	1.87e-05	0.000136	CcSEcCtD
Azelastine—Anxiety—Epirubicin—hematologic cancer	1.87e-05	0.000135	CcSEcCtD
Azelastine—Pruritus—Dexamethasone—hematologic cancer	1.86e-05	0.000135	CcSEcCtD
Azelastine—Pruritus—Betamethasone—hematologic cancer	1.86e-05	0.000135	CcSEcCtD
Azelastine—Discomfort—Epirubicin—hematologic cancer	1.85e-05	0.000134	CcSEcCtD
Azelastine—Vomiting—Triamcinolone—hematologic cancer	1.85e-05	0.000134	CcSEcCtD
Azelastine—Malaise—Doxorubicin—hematologic cancer	1.83e-05	0.000133	CcSEcCtD
Azelastine—Rash—Triamcinolone—hematologic cancer	1.83e-05	0.000133	CcSEcCtD
Azelastine—Dry mouth—Epirubicin—hematologic cancer	1.83e-05	0.000133	CcSEcCtD
Azelastine—Dermatitis—Triamcinolone—hematologic cancer	1.83e-05	0.000133	CcSEcCtD
Azelastine—Vertigo—Doxorubicin—hematologic cancer	1.83e-05	0.000132	CcSEcCtD
Azelastine—Headache—Triamcinolone—hematologic cancer	1.82e-05	0.000132	CcSEcCtD
Azelastine—Body temperature increased—Prednisone—hematologic cancer	1.81e-05	0.000131	CcSEcCtD
Azelastine—Abdominal pain—Prednisone—hematologic cancer	1.81e-05	0.000131	CcSEcCtD
Azelastine—Confusional state—Epirubicin—hematologic cancer	1.81e-05	0.000131	CcSEcCtD
Azelastine—Diarrhoea—Betamethasone—hematologic cancer	1.8e-05	0.000131	CcSEcCtD
Azelastine—Diarrhoea—Dexamethasone—hematologic cancer	1.8e-05	0.000131	CcSEcCtD
Azelastine—Palpitations—Doxorubicin—hematologic cancer	1.8e-05	0.00013	CcSEcCtD
Azelastine—Anaphylactic shock—Epirubicin—hematologic cancer	1.79e-05	0.00013	CcSEcCtD
Azelastine—Infection—Epirubicin—hematologic cancer	1.78e-05	0.000129	CcSEcCtD
Azelastine—Cough—Doxorubicin—hematologic cancer	1.77e-05	0.000129	CcSEcCtD
Azelastine—Hypertension—Doxorubicin—hematologic cancer	1.76e-05	0.000127	CcSEcCtD
Azelastine—Tachycardia—Epirubicin—hematologic cancer	1.75e-05	0.000127	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.75e-05	0.000127	CcSEcCtD
Azelastine—Dizziness—Dexamethasone—hematologic cancer	1.74e-05	0.000126	CcSEcCtD
Azelastine—Dizziness—Betamethasone—hematologic cancer	1.74e-05	0.000126	CcSEcCtD
Azelastine—Chest pain—Doxorubicin—hematologic cancer	1.73e-05	0.000126	CcSEcCtD
Azelastine—Myalgia—Doxorubicin—hematologic cancer	1.73e-05	0.000126	CcSEcCtD
Azelastine—Anxiety—Doxorubicin—hematologic cancer	1.73e-05	0.000125	CcSEcCtD
Azelastine—Nausea—Triamcinolone—hematologic cancer	1.72e-05	0.000125	CcSEcCtD
Azelastine—Paraesthesia—Methotrexate—hematologic cancer	1.72e-05	0.000125	CcSEcCtD
Azelastine—Discomfort—Doxorubicin—hematologic cancer	1.71e-05	0.000124	CcSEcCtD
Azelastine—Dyspnoea—Methotrexate—hematologic cancer	1.71e-05	0.000124	CcSEcCtD
Azelastine—Somnolence—Methotrexate—hematologic cancer	1.7e-05	0.000124	CcSEcCtD
Azelastine—Dry mouth—Doxorubicin—hematologic cancer	1.69e-05	0.000123	CcSEcCtD
Azelastine—Hypersensitivity—Prednisone—hematologic cancer	1.69e-05	0.000123	CcSEcCtD
Azelastine—Vomiting—Betamethasone—hematologic cancer	1.67e-05	0.000121	CcSEcCtD
Azelastine—Vomiting—Dexamethasone—hematologic cancer	1.67e-05	0.000121	CcSEcCtD
Azelastine—Confusional state—Doxorubicin—hematologic cancer	1.67e-05	0.000121	CcSEcCtD
Azelastine—Rash—Dexamethasone—hematologic cancer	1.66e-05	0.00012	CcSEcCtD
Azelastine—Rash—Betamethasone—hematologic cancer	1.66e-05	0.00012	CcSEcCtD
Azelastine—Anaphylactic shock—Doxorubicin—hematologic cancer	1.66e-05	0.00012	CcSEcCtD
Azelastine—Dermatitis—Dexamethasone—hematologic cancer	1.66e-05	0.00012	CcSEcCtD
Azelastine—Dermatitis—Betamethasone—hematologic cancer	1.66e-05	0.00012	CcSEcCtD
Azelastine—Fatigue—Methotrexate—hematologic cancer	1.65e-05	0.00012	CcSEcCtD
Azelastine—Headache—Betamethasone—hematologic cancer	1.65e-05	0.00012	CcSEcCtD
Azelastine—Headache—Dexamethasone—hematologic cancer	1.65e-05	0.00012	CcSEcCtD
Azelastine—Infection—Doxorubicin—hematologic cancer	1.65e-05	0.00012	CcSEcCtD
Azelastine—Asthenia—Prednisone—hematologic cancer	1.65e-05	0.000119	CcSEcCtD
Azelastine—Pain—Methotrexate—hematologic cancer	1.64e-05	0.000119	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.63e-05	0.000118	CcSEcCtD
Azelastine—Pruritus—Prednisone—hematologic cancer	1.62e-05	0.000118	CcSEcCtD
Azelastine—Tachycardia—Doxorubicin—hematologic cancer	1.62e-05	0.000117	CcSEcCtD
Azelastine—Paraesthesia—Epirubicin—hematologic cancer	1.61e-05	0.000117	CcSEcCtD
Azelastine—Dyspnoea—Epirubicin—hematologic cancer	1.6e-05	0.000116	CcSEcCtD
Azelastine—Somnolence—Epirubicin—hematologic cancer	1.59e-05	0.000116	CcSEcCtD
Azelastine—Feeling abnormal—Methotrexate—hematologic cancer	1.58e-05	0.000115	CcSEcCtD
Azelastine—Diarrhoea—Prednisone—hematologic cancer	1.57e-05	0.000114	CcSEcCtD
Azelastine—Gastrointestinal pain—Methotrexate—hematologic cancer	1.57e-05	0.000114	CcSEcCtD
Azelastine—Nausea—Dexamethasone—hematologic cancer	1.56e-05	0.000113	CcSEcCtD
Azelastine—Nausea—Betamethasone—hematologic cancer	1.56e-05	0.000113	CcSEcCtD
Azelastine—Fatigue—Epirubicin—hematologic cancer	1.55e-05	0.000112	CcSEcCtD
Azelastine—Pain—Epirubicin—hematologic cancer	1.53e-05	0.000111	CcSEcCtD
Azelastine—Constipation—Epirubicin—hematologic cancer	1.53e-05	0.000111	CcSEcCtD
Azelastine—Dizziness—Prednisone—hematologic cancer	1.52e-05	0.00011	CcSEcCtD
Azelastine—Abdominal pain—Methotrexate—hematologic cancer	1.52e-05	0.00011	CcSEcCtD
Azelastine—Body temperature increased—Methotrexate—hematologic cancer	1.52e-05	0.00011	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.51e-05	0.00011	CcSEcCtD
Azelastine—Paraesthesia—Doxorubicin—hematologic cancer	1.49e-05	0.000108	CcSEcCtD
Azelastine—Dyspnoea—Doxorubicin—hematologic cancer	1.48e-05	0.000107	CcSEcCtD
Azelastine—Feeling abnormal—Epirubicin—hematologic cancer	1.48e-05	0.000107	CcSEcCtD
Azelastine—Somnolence—Doxorubicin—hematologic cancer	1.48e-05	0.000107	CcSEcCtD
Azelastine—Gastrointestinal pain—Epirubicin—hematologic cancer	1.47e-05	0.000106	CcSEcCtD
Azelastine—Vomiting—Prednisone—hematologic cancer	1.46e-05	0.000106	CcSEcCtD
Azelastine—Rash—Prednisone—hematologic cancer	1.45e-05	0.000105	CcSEcCtD
Azelastine—Dermatitis—Prednisone—hematologic cancer	1.45e-05	0.000105	CcSEcCtD
Azelastine—Headache—Prednisone—hematologic cancer	1.44e-05	0.000104	CcSEcCtD
Azelastine—Fatigue—Doxorubicin—hematologic cancer	1.43e-05	0.000104	CcSEcCtD
Azelastine—Constipation—Doxorubicin—hematologic cancer	1.42e-05	0.000103	CcSEcCtD
Azelastine—Pain—Doxorubicin—hematologic cancer	1.42e-05	0.000103	CcSEcCtD
Azelastine—Body temperature increased—Epirubicin—hematologic cancer	1.42e-05	0.000103	CcSEcCtD
Azelastine—Abdominal pain—Epirubicin—hematologic cancer	1.42e-05	0.000103	CcSEcCtD
Azelastine—Hypersensitivity—Methotrexate—hematologic cancer	1.41e-05	0.000102	CcSEcCtD
Azelastine—Asthenia—Methotrexate—hematologic cancer	1.38e-05	9.97e-05	CcSEcCtD
Azelastine—Feeling abnormal—Doxorubicin—hematologic cancer	1.37e-05	9.92e-05	CcSEcCtD
Azelastine—Nausea—Prednisone—hematologic cancer	1.36e-05	9.88e-05	CcSEcCtD
Azelastine—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.36e-05	9.84e-05	CcSEcCtD
Azelastine—Pruritus—Methotrexate—hematologic cancer	1.36e-05	9.83e-05	CcSEcCtD
Azelastine—Hypersensitivity—Epirubicin—hematologic cancer	1.32e-05	9.58e-05	CcSEcCtD
Azelastine—Body temperature increased—Doxorubicin—hematologic cancer	1.31e-05	9.51e-05	CcSEcCtD
Azelastine—Abdominal pain—Doxorubicin—hematologic cancer	1.31e-05	9.51e-05	CcSEcCtD
Azelastine—Diarrhoea—Methotrexate—hematologic cancer	1.31e-05	9.51e-05	CcSEcCtD
Azelastine—Asthenia—Epirubicin—hematologic cancer	1.29e-05	9.33e-05	CcSEcCtD
Azelastine—Pruritus—Epirubicin—hematologic cancer	1.27e-05	9.2e-05	CcSEcCtD
Azelastine—Dizziness—Methotrexate—hematologic cancer	1.27e-05	9.19e-05	CcSEcCtD
Azelastine—Diarrhoea—Epirubicin—hematologic cancer	1.23e-05	8.9e-05	CcSEcCtD
Azelastine—Hypersensitivity—Doxorubicin—hematologic cancer	1.22e-05	8.87e-05	CcSEcCtD
Azelastine—Vomiting—Methotrexate—hematologic cancer	1.22e-05	8.84e-05	CcSEcCtD
Azelastine—Rash—Methotrexate—hematologic cancer	1.21e-05	8.76e-05	CcSEcCtD
Azelastine—Dermatitis—Methotrexate—hematologic cancer	1.21e-05	8.75e-05	CcSEcCtD
Azelastine—Headache—Methotrexate—hematologic cancer	1.2e-05	8.71e-05	CcSEcCtD
Azelastine—Asthenia—Doxorubicin—hematologic cancer	1.19e-05	8.63e-05	CcSEcCtD
Azelastine—Dizziness—Epirubicin—hematologic cancer	1.19e-05	8.6e-05	CcSEcCtD
Azelastine—Pruritus—Doxorubicin—hematologic cancer	1.17e-05	8.51e-05	CcSEcCtD
Azelastine—Vomiting—Epirubicin—hematologic cancer	1.14e-05	8.27e-05	CcSEcCtD
Azelastine—Nausea—Methotrexate—hematologic cancer	1.14e-05	8.26e-05	CcSEcCtD
Azelastine—Diarrhoea—Doxorubicin—hematologic cancer	1.14e-05	8.23e-05	CcSEcCtD
Azelastine—Rash—Epirubicin—hematologic cancer	1.13e-05	8.2e-05	CcSEcCtD
Azelastine—Dermatitis—Epirubicin—hematologic cancer	1.13e-05	8.19e-05	CcSEcCtD
Azelastine—Headache—Epirubicin—hematologic cancer	1.12e-05	8.15e-05	CcSEcCtD
Azelastine—Dizziness—Doxorubicin—hematologic cancer	1.1e-05	7.96e-05	CcSEcCtD
Azelastine—Nausea—Epirubicin—hematologic cancer	1.07e-05	7.73e-05	CcSEcCtD
Azelastine—Vomiting—Doxorubicin—hematologic cancer	1.06e-05	7.65e-05	CcSEcCtD
Azelastine—Rash—Doxorubicin—hematologic cancer	1.05e-05	7.59e-05	CcSEcCtD
Azelastine—Dermatitis—Doxorubicin—hematologic cancer	1.05e-05	7.58e-05	CcSEcCtD
Azelastine—Headache—Doxorubicin—hematologic cancer	1.04e-05	7.54e-05	CcSEcCtD
Azelastine—Nausea—Doxorubicin—hematologic cancer	9.86e-06	7.15e-05	CcSEcCtD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.91e-06	3.75e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.9e-06	3.74e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—MTR—hematologic cancer	1.9e-06	3.74e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NFKBIA—hematologic cancer	1.9e-06	3.74e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—BAD—hematologic cancer	1.9e-06	3.74e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GSTP1—hematologic cancer	1.9e-06	3.73e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—MTHFR—hematologic cancer	1.9e-06	3.73e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CCL2—hematologic cancer	1.9e-06	3.72e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL6R—hematologic cancer	1.89e-06	3.71e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CREBBP—hematologic cancer	1.89e-06	3.71e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NOTCH1—hematologic cancer	1.89e-06	3.7e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CG—hematologic cancer	1.89e-06	3.7e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—NCOR1—hematologic cancer	1.87e-06	3.67e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GSTM1—hematologic cancer	1.87e-06	3.67e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ENO2—hematologic cancer	1.87e-06	3.66e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CD80—hematologic cancer	1.85e-06	3.62e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CG—hematologic cancer	1.85e-06	3.62e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CYCS—hematologic cancer	1.85e-06	3.62e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CG—hematologic cancer	1.84e-06	3.62e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KIT—hematologic cancer	1.84e-06	3.62e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—NRAS—hematologic cancer	1.84e-06	3.62e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CG—hematologic cancer	1.84e-06	3.61e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.84e-06	3.61e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	1.83e-06	3.6e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.83e-06	3.58e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ABCB1—hematologic cancer	1.82e-06	3.57e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PTPN11—hematologic cancer	1.81e-06	3.55e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.81e-06	3.55e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MAP2K1—hematologic cancer	1.8e-06	3.54e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ABCB1—hematologic cancer	1.8e-06	3.53e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CD—hematologic cancer	1.79e-06	3.51e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CB—hematologic cancer	1.79e-06	3.51e-05	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—PIK3CA—hematologic cancer	1.77e-06	3.48e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—SDC1—hematologic cancer	1.77e-06	3.47e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—MAPK3—hematologic cancer	1.77e-06	3.46e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—NCOR1—hematologic cancer	1.76e-06	3.46e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GSTM1—hematologic cancer	1.76e-06	3.46e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CREB1—hematologic cancer	1.76e-06	3.44e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—KRAS—hematologic cancer	1.75e-06	3.44e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—NCOR1—hematologic cancer	1.75e-06	3.43e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GSTM1—hematologic cancer	1.75e-06	3.43e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—CREBBP—hematologic cancer	1.75e-06	3.43e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CG—hematologic cancer	1.74e-06	3.41e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—BRAF—hematologic cancer	1.73e-06	3.4e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CCL2—hematologic cancer	1.72e-06	3.37e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—FGF2—hematologic cancer	1.71e-06	3.36e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL6R—hematologic cancer	1.71e-06	3.36e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—CREBBP—hematologic cancer	1.71e-06	3.36e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CREBBP—hematologic cancer	1.71e-06	3.35e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—CREBBP—hematologic cancer	1.71e-06	3.35e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—MTHFR—hematologic cancer	1.7e-06	3.33e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3R1—hematologic cancer	1.69e-06	3.32e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.67e-06	3.28e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CD—hematologic cancer	1.66e-06	3.25e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—MTHFR—hematologic cancer	1.66e-06	3.25e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.65e-06	3.24e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—JAK2—hematologic cancer	1.64e-06	3.22e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—ALB—hematologic cancer	1.64e-06	3.21e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MAP2K1—hematologic cancer	1.63e-06	3.2e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GSTP1—hematologic cancer	1.63e-06	3.19e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CD—hematologic cancer	1.62e-06	3.18e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CD—hematologic cancer	1.62e-06	3.18e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CD—hematologic cancer	1.62e-06	3.18e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—CREBBP—hematologic cancer	1.61e-06	3.17e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—PIK3CA—hematologic cancer	1.61e-06	3.16e-05	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.61e-06	3.15e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MDM2—hematologic cancer	1.6e-06	3.15e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—ALB—hematologic cancer	1.6e-06	3.14e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—ALB—hematologic cancer	1.6e-06	3.14e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CG—hematologic cancer	1.6e-06	3.13e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—KRAS—hematologic cancer	1.59e-06	3.11e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.57e-06	3.09e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3R1—hematologic cancer	1.57e-06	3.07e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CB—hematologic cancer	1.56e-06	3.06e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MTOR—hematologic cancer	1.56e-06	3.06e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—MTHFR—hematologic cancer	1.56e-06	3.06e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—FGF2—hematologic cancer	1.55e-06	3.04e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PTEN—hematologic cancer	1.55e-06	3.03e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.55e-06	3.03e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ABCB1—hematologic cancer	1.54e-06	3.02e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3R1—hematologic cancer	1.53e-06	3.01e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3R1—hematologic cancer	1.53e-06	3e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CD—hematologic cancer	1.53e-06	3e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3R1—hematologic cancer	1.53e-06	3e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—ALB—hematologic cancer	1.51e-06	2.96e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NQO1—hematologic cancer	1.51e-06	2.95e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CD44—hematologic cancer	1.51e-06	2.95e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GSTM1—hematologic cancer	1.49e-06	2.93e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—NCOR1—hematologic cancer	1.49e-06	2.93e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.49e-06	2.93e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—HRAS—hematologic cancer	1.49e-06	2.92e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—JAK2—hematologic cancer	1.49e-06	2.92e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CREBBP—hematologic cancer	1.48e-06	2.9e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—EP300—hematologic cancer	1.48e-06	2.89e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CDKN1B—hematologic cancer	1.47e-06	2.87e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—PIK3CA—hematologic cancer	1.46e-06	2.86e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MDM2—hematologic cancer	1.45e-06	2.85e-05	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—AKT1—hematologic cancer	1.45e-06	2.84e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3R1—hematologic cancer	1.45e-06	2.83e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CB—hematologic cancer	1.44e-06	2.83e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CASP3—hematologic cancer	1.44e-06	2.82e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL2—hematologic cancer	1.43e-06	2.81e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—IL6—hematologic cancer	1.43e-06	2.8e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.42e-06	2.79e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYCS—hematologic cancer	1.42e-06	2.79e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.42e-06	2.78e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CB—hematologic cancer	1.41e-06	2.78e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CB—hematologic cancer	1.41e-06	2.77e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MTOR—hematologic cancer	1.41e-06	2.77e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CB—hematologic cancer	1.41e-06	2.77e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CD—hematologic cancer	1.4e-06	2.75e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CCND1—hematologic cancer	1.4e-06	2.74e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—JUN—hematologic cancer	1.39e-06	2.74e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.39e-06	2.73e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—ALB—hematologic cancer	1.39e-06	2.72e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.36e-06	2.67e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	1.35e-06	2.65e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—HRAS—hematologic cancer	1.35e-06	2.65e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	1.35e-06	2.65e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CB—hematologic cancer	1.33e-06	2.62e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CDKN1B—hematologic cancer	1.33e-06	2.6e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3R1—hematologic cancer	1.32e-06	2.6e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.32e-06	2.59e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.32e-06	2.59e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	1.32e-06	2.59e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	1.32e-06	2.58e-05	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—AKT1—hematologic cancer	1.31e-06	2.57e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.31e-06	2.57e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CASP3—hematologic cancer	1.3e-06	2.55e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.3e-06	2.55e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL2—hematologic cancer	1.3e-06	2.55e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—IL6—hematologic cancer	1.29e-06	2.53e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CREBBP—hematologic cancer	1.29e-06	2.53e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EP300—hematologic cancer	1.29e-06	2.52e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CCND1—hematologic cancer	1.27e-06	2.48e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—JUN—hematologic cancer	1.26e-06	2.48e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.26e-06	2.46e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CD—hematologic cancer	1.25e-06	2.46e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—SRC—hematologic cancer	1.25e-06	2.45e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTEN—hematologic cancer	1.25e-06	2.45e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—ALB—hematologic cancer	1.24e-06	2.43e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	1.22e-06	2.4e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CB—hematologic cancer	1.22e-06	2.4e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTEN—hematologic cancer	1.22e-06	2.4e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.22e-06	2.4e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PTEN—hematologic cancer	1.22e-06	2.4e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTEN—hematologic cancer	1.22e-06	2.39e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	1.22e-06	2.39e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.21e-06	2.38e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—ALB—hematologic cancer	1.21e-06	2.37e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	1.21e-06	2.37e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.2e-06	2.36e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	1.2e-06	2.36e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MAPK8—hematologic cancer	1.19e-06	2.34e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—AKT1—hematologic cancer	1.19e-06	2.34e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—EP300—hematologic cancer	1.19e-06	2.34e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.19e-06	2.33e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.18e-06	2.32e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—EP300—hematologic cancer	1.17e-06	2.29e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EP300—hematologic cancer	1.16e-06	2.28e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.16e-06	2.28e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—EP300—hematologic cancer	1.16e-06	2.28e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.15e-06	2.26e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.15e-06	2.26e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.15e-06	2.26e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTEN—hematologic cancer	1.15e-06	2.26e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	1.15e-06	2.26e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.15e-06	2.26e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.14e-06	2.24e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ALB—hematologic cancer	1.14e-06	2.23e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—SRC—hematologic cancer	1.13e-06	2.22e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ALB—hematologic cancer	1.13e-06	2.21e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MYC—hematologic cancer	1.12e-06	2.2e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	1.12e-06	2.19e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.11e-06	2.18e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—VEGFA—hematologic cancer	1.1e-06	2.16e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—EP300—hematologic cancer	1.1e-06	2.16e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—STAT3—hematologic cancer	1.09e-06	2.14e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.09e-06	2.14e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CA—hematologic cancer	1.09e-06	2.14e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NRAS—hematologic cancer	1.09e-06	2.14e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.09e-06	2.13e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.08e-06	2.12e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.07e-06	2.09e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTEN—hematologic cancer	1.06e-06	2.07e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MAPK3—hematologic cancer	1.04e-06	2.05e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	1.04e-06	2.03e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.03e-06	2.02e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.02e-06	2e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MYC—hematologic cancer	1.01e-06	1.99e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TGFB1—hematologic cancer	1.01e-06	1.99e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—EP300—hematologic cancer	1.01e-06	1.98e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1e-06	1.97e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CB—hematologic cancer	9.95e-07	1.95e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	9.76e-07	1.91e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ALB—hematologic cancer	9.63e-07	1.89e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	9.52e-07	1.87e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTEN—hematologic cancer	9.43e-07	1.85e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KRAS—hematologic cancer	9.38e-07	1.84e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	9.21e-07	1.81e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTEN—hematologic cancer	9.21e-07	1.81e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TP53—hematologic cancer	9.21e-07	1.81e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—EP300—hematologic cancer	9e-07	1.76e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—AKT1—hematologic cancer	8.92e-07	1.75e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CA—hematologic cancer	8.81e-07	1.73e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	8.8e-07	1.73e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—EP300—hematologic cancer	8.78e-07	1.72e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTEN—hematologic cancer	8.68e-07	1.7e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CA—hematologic cancer	8.63e-07	1.69e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	8.61e-07	1.69e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CA—hematologic cancer	8.61e-07	1.69e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTEN—hematologic cancer	8.6e-07	1.69e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	8.57e-07	1.68e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	8.51e-07	1.67e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL6—hematologic cancer	8.43e-07	1.65e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TP53—hematologic cancer	8.33e-07	1.63e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—EP300—hematologic cancer	8.27e-07	1.62e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—EP300—hematologic cancer	8.2e-07	1.61e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CA—hematologic cancer	8.13e-07	1.6e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—HRAS—hematologic cancer	7.97e-07	1.56e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CREBBP—hematologic cancer	7.94e-07	1.56e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	7.77e-07	1.52e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL6—hematologic cancer	7.63e-07	1.5e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	7.53e-07	1.48e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CA—hematologic cancer	7.46e-07	1.46e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ALB—hematologic cancer	7.43e-07	1.46e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTEN—hematologic cancer	7.35e-07	1.44e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—AKT1—hematologic cancer	7.19e-07	1.41e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	7.11e-07	1.39e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—AKT1—hematologic cancer	7.05e-07	1.38e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—AKT1—hematologic cancer	7.04e-07	1.38e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—AKT1—hematologic cancer	7.03e-07	1.38e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—EP300—hematologic cancer	7.01e-07	1.37e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CA—hematologic cancer	6.65e-07	1.31e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—AKT1—hematologic cancer	6.64e-07	1.3e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	6.56e-07	1.29e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CA—hematologic cancer	6.5e-07	1.27e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	6.12e-07	1.2e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—AKT1—hematologic cancer	6.09e-07	1.19e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CA—hematologic cancer	6.07e-07	1.19e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTEN—hematologic cancer	5.67e-07	1.11e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—AKT1—hematologic cancer	5.44e-07	1.07e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—EP300—hematologic cancer	5.41e-07	1.06e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—AKT1—hematologic cancer	5.31e-07	1.04e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	5.19e-07	1.02e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—AKT1—hematologic cancer	5e-07	9.81e-06	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—AKT1—hematologic cancer	4.96e-07	9.72e-06	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—AKT1—hematologic cancer	4.24e-07	8.31e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	4e-07	7.85e-06	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—AKT1—hematologic cancer	3.27e-07	6.41e-06	CbGpPWpGaD
